Dr. MiltieAtlas by Dr. Miltie™Nationwide Grant Intelligence
Verification Pending — official Grants.gov candidate (posted)
HT942526ARPCTA

DoW Autism Clinical Trial Award

Official Grants.gov opportunity HT942526ARPCTA from JoAnn Martin Grantor. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.

FundingApplicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Deadline2026-10-22 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.

Broad Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Official funding announcement — preliminary draft

Funder: JoAnn Martin Grantor

Opportunity number: HT942526ARPCTA

Official listed status: posted

Closing information: 2026-10-22 (official deadline clock time and time zone must be checked in NOFO)

Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.

Applicant categories in federal synopsis: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Federal synopsis

Summary: The fiscal year 2026 (FY26) Autism Research Program (ARP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of autism. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.Distinctive Features: Applications are strongly encouraged to address one of the FY26 ARP Clinical Trial Award Areas of Interest.Partnering Principal Investigator (PI) Option for Early-Career Investigator: The FY26 Clinical Trial Award mechanism is offering a higher level of funding for applications that propose to partner an experienced PI (i.e., Initiating PI) with an Early-Career Investigator (i.e., Partnering PI) wishing to pursue a career in autism clinical trial research.FY26 Clinical Trial Award submissions are required to include community collaborations to optimize research impact. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research. Applications to the FY26 ARP Clinical Trial Award are expected to name at least one community partner (e.g., Autistic individual or caregiver, representatives of community-based organizations) who …

Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.

Official Grants.gov opportunity and NOFO

Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗